Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Clinical trial NCT05445778 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05445778
Sponsor: AbbVie
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Ovarian Cancer Peritoneal Cancer Fallopian Tube Cancer

Start date: 2023-03-15
Primary completion: 2027-04-01
Enrollment: 520

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.